Literature DB >> 16275822

Oxcarbazepine adjunctive therapy in infants and young children with partial seizures.

J E Piña-Garza1, R Espinoza, D Nordli, D A Bennett, S Spirito, T E Stites, D Tang, Y Sturm.   

Abstract

OBJECTIVE: To evaluate the efficacy, safety, and pharmacokinetics of oxcarbazepine as adjunctive therapy in infants and young children (1 month to < 4 years).
METHODS: Children 1 month to < 4 years of age with inadequately controlled partial seizures taking up to two concomitant antiepileptic drugs (AEDs) were enrolled in this rater-blind, randomized, parallel-group study. Patients received either high-dose (60 mg/kg/day) or low-dose (10 mg/kg/day) oxcarbazepine as oral suspension. The primary efficacy variable was the absolute change in electrographic partial seizures with a behavioral correlate (type 1 seizure) frequency per 24 hours during the last 72 hours of continuous video-EEG monitoring in the treatment phase compared with baseline seizure frequency.
RESULTS: Of 191 patients screened, 128 were randomized: 64 to both oxcarbazepine dose groups. The median absolute change in type 1 seizure frequency per 24 hours was more effective for the high-dose group (-2.00) compared with the low-dose group (-1.37; p = 0.043). The median percentage reduction in type 1 seizure frequency per 24 hours was also greater in the high-dose group (83.33%) than in the low-dose group (46.18%; p = 0.047). The most frequent adverse events (> or = 10%) were somnolence and pyrexia, and most were mild in severity.
CONCLUSIONS: In this study, high-dose oxcarbazepine was significantly more effective than low-dose oxcarbazepine in controlling partial seizures in infants and very young children.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16275822     DOI: 10.1212/01.wnl.0000186800.18456.72

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  28 in total

Review 1.  Clinical development of antiepileptic drugs for children.

Authors:  Elizabeth Garofalo
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

2.  EEG for children with complex febrile seizures.

Authors:  Pankaj B Shah; Saji James; Sivaprakasam Elayaraja
Journal:  Cochrane Database Syst Rev       Date:  2020-04-09

3.  Safety and transparency of pediatric drug trials.

Authors:  Daniel K Benjamin; P Brian Smith; M Jessica M Sun; M Dianne Murphy; Debbie Avant; Lisa Mathis; William Rodriguez; Robert M Califf; Jennifer S Li
Journal:  Arch Pediatr Adolesc Med       Date:  2009-12

Review 4.  WITHDRAWN: Oxcarbazepine add-on for drug-resistant partial epilepsy.

Authors:  Sergio M Castillo; Dieter B Schmidt; Sarah White; Arif Shukralla
Journal:  Cochrane Database Syst Rev       Date:  2016-11-15

5.  Oxcarbazepine oral suspension in young pediatric patients with partial seizures and/or generalized tonic-clonic seizures in routine clinical practice in China: a prospective observational study.

Authors:  Jiong Qin; Yi Wang; Xin-Fang Huang; Yu-Qin Zhang; Fang Fang; Yin-Bo Chen; Zhong-Dong Lin; Yan-Chun Deng; Fei Yin; Li Jiang; Ye Wu; Xiang-Shu Hu
Journal:  World J Pediatr       Date:  2018-02-20       Impact factor: 2.764

Review 6.  Pharmacotherapy for Focal Seizures in Children and Adolescents.

Authors:  Clare E Stevens; Carl E Stafstrom
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

7.  Newer anticonvulsant medications in pediatric neurology.

Authors:  Michael M Quach; Abdul Mazin; James J Riviello
Journal:  Curr Treat Options Neurol       Date:  2010-11       Impact factor: 3.598

8.  Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens.

Authors:  Wei-Wei Lin; Xi-Wen Li; Zheng Jiao; Jin Zhang; Xin Rao; Da-Yong Zeng; Xin-Hua Lin; Chang-Lian Wang
Journal:  Eur J Clin Pharmacol       Date:  2018-11-19       Impact factor: 2.953

Review 9.  A revisited strategy for antiepileptic drug development in children: designing an initial exploratory step.

Authors:  Catherine Chiron; Behrouz Kassai; Olivier Dulac; Gerard Pons; Rima Nabbout
Journal:  CNS Drugs       Date:  2013-03       Impact factor: 5.749

Review 10.  Use of second-generation antiepileptic drugs in the pediatric population.

Authors:  Allison M Chung; Lea S Eiland
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.